AVNS · As filed with the SEC
Avanos Medical balance sheet, by quarter
The statement as Avanos Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 |
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash and cash equivalents | 65,600,000 | 89,800,000 | 70,500,000 | 90,300,000 |
| Accounts receivable, net of allowances | 103,000,000 | 103,800,000 | 111,500,000 | 110,200,000 |
| Inventories | 141,300,000 | 148,000,000 | 150,600,000 | 142,700,000 |
| Prepaid and other current assets | 15,100,000 | 13,800,000 | 18,800,000 | 12,800,000 |
| Total Current Assets | 325,000,000 | 355,400,000 | 351,400,000 | 356,000,000 |
| Property, Plant and Equipment, net | 111,200,000 | 113,400,000 | 115,400,000 | 114,300,000 |
| Operating Lease Right-of-Use Assets | 39,300,000 | 27,600,000 | 29,900,000 | 31,100,000 |
| Goodwill | 394,000,000 | 394,900,000 | 394,400,000 | 381,200,000 |
| Other Intangible Assets, net | 114,700,000 | 117,800,000 | 122,000,000 | 105,400,000 |
| Deferred Tax Assets | 33,000,000 | 33,100,000 | 25,300,000 | 25,300,000 |
| Other Assets | 32,900,000 | 31,500,000 | 29,300,000 | 25,700,000 |
| TOTAL ASSETS | 1,050,100,000 | 1,073,700,000 | 1,067,700,000 | 1,039,000,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current Liabilities | ||||
| Current portion of long-term debt | 10,900,000 | 10,200,000 | 9,400,000 | 9,400,000 |
| Current portion of operating lease liabilities | 10,400,000 | 8,200,000 | 9,500,000 | 10,400,000 |
| Trade accounts payable | 52,300,000 | 55,500,000 | 54,200,000 | 48,800,000 |
| Accrued expenses | 57,600,000 | 91,300,000 | 74,800,000 | 66,000,000 |
| Total Current Liabilities | 131,200,000 | 165,200,000 | 147,900,000 | 134,600,000 |
| Long-Term Debt | 87,300,000 | 90,300,000 | 93,400,000 | 95,700,000 |
| Operating Lease Liabilities | 29,800,000 | 20,400,000 | 21,400,000 | 21,800,000 |
| Deferred Tax Liabilities | 5,600,000 | 6,100,000 | 6,300,000 | 6,300,000 |
| Other Long-Term Liabilities | 14,100,000 | 13,500,000 | 20,700,000 | 4,300,000 |
| Total Liabilities | 268,000,000 | 295,500,000 | 289,700,000 | 262,700,000 |
| Stockholders’ Equity | ||||
| Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued | 0 | 0 | 0 | 0 |
| Common stock - $0.01 par value - authorized 300,000,000 shares, 46,673,069 outstanding as of March 31, 2026 and 46,456,462 outstanding as of December 31, 2025 | 500,000 | 500,000 | 500,000 | 500,000 |
| Additional paid-in capital | 1,696,000,000 | 1,691,900,000 | 1,690,700,000 | 1,686,900,000 |
| Accumulated deficit | (774,800,000) | (779,900,000) | (778,600,000) | (777,200,000) |
| Treasury stock | (103,600,000) | (102,300,000) | (102,000,000) | (101,900,000) |
| Accumulated other comprehensive loss | (36,000,000) | (32,000,000) | (32,600,000) | (32,000,000) |
| Total Stockholders’ Equity | 782,100,000 | 778,200,000 | 778,000,000 | 776,300,000 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 1,050,100,000 | 1,073,700,000 | 1,067,700,000 | 1,039,000,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.